Midterm Results of Descemet Membrane Endothelial Keratoplasty: 4 to 7 Years Clinical Outcome




Purpose


To evaluate the midterm outcomes of Descemet membrane endothelial keratoplasty (DMEK) up to 4–7 years postoperatively.


Design


Retrospective, consecutive interventional case series.


Methods


A total of 250 consecutive eyes of 209 patients who underwent DMEK at our institute and had potentially at least 4 years of follow-up. Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell density (ECD), central corneal thickness (CCT), graft survival rate, and postoperative complications.


Results


At 6 months postoperatively, 73% of the eyes reached a BCVA of ≥20/25 (0.8) and 44% ≥20/20 (1.0), and remained stable up to 7 years ( P = .7114). ECD dropped by 33.9% in the first 6 months, and then declined by a yearly rate of 9.0%. CCT did not show a significant change after 6 months up to 7 years ( P = .8447). The cumulative graft survival rate at 4 and 7 years was 0.96 (95% confidence interval [0.93, 0.99]). Rebubbling procedures were performed in 4.4% of eyes, all within the first 6 postoperative months. Repeat transplantations were performed in 15.2% of cases to manage greater than one third graft detachment (11.6%), primary graft failure (1.6%), or secondary graft failure (2.0%), with the majority (79%) of repeat transplantations performed within the first year. After 6 months, the main complications were allograft rejection (2.4%) and secondary graft failure (2.0%).


Conclusions


The visual acuity level achieved at 6 months after DMEK may remain stable up to at least 4–7 years; ECD shows a constant, slow decrease; and complications after the first 6 months occur in <5% of cases.


Endothelial keratoplasty (EK) has become the preferred treatment option for managing corneal endothelial disorders. Although Descemet stripping (automated) endothelial keratoplasty (DSEK/DSAEK) might be the most widely applied method today, selective transplantation of Descemet membrane (DM) and endothelium, referred to as Descemet membrane endothelial keratoplasty (DMEK), is gaining more and more popularity.


Although various studies have confirmed the main advantages of EK over penetrating keratoplasty—that is, better visual outcomes, faster rehabilitation, and lower risk of long-term complications—there is limited information on the results of EK over a period of 5 years or more.


For deep lamellar endothelial keratoplasty, an 84% graft survival rate at 8–12 years was reported; and for DSEK/DSAEK a graft survival rate of 95% was found at 5 years. Both of these procedures have also shown stable visual results over these postoperative intervals. For DMEK a 96% graft survival rate at 5–8 years was found. However, longer-term results regarding visual outcomes, endothelial cell density (ECD), and the occurrence of late postoperative complications have not yet been comprehensively described since the procedure was introduced clinically in 2006.


The purpose of this study, therefore, was to report the midterm (up to 4–7 years) clinical outcomes in the first DMEK patient cohort worldwide.


Methods


A total of 250 consecutive eyes (209 patients; mean [± standard deviation] age 67 [± 13] years; range 30–93 years), including the learning curve of the first 25 DMEK eyes, underwent DMEK for Fuchs endothelial dystrophy, pseudophakic bullous keratopathy (BK), BK after phakic intraocular lens implantation, buphthalmos, or corneal perforation, as well as for failed corneal transplant (penetrating keratoplasty or DSEK/DSAEK) ( Table 1 ). Both phakic (20.4%) and pseudophakic eyes were included. The retrospective study was conducted with patient informed consent prior to surgery in compliance with the Institutional Review Board and informed consent requirements at the Netherlands Institute for Innovative Ocular Surgery, in adherence to the tenets of the Declaration of Helsinki.



Table 1

Demographics of Descemet Membrane Endothelial Keratoplasty Eyes




































Demographics (N = 250 DMEK Eyes)
Number of eyes 250
Number of patients 209
Mean age (±SD) [range] 67.3 (±12.5) years [30–93 years]
Male/female, n [%] 93/116 [44.5%/55.5%]
Phakic eyes, n [%] 51 [20.4%]
Indication, n [%]
Fuchs endothelial dystrophy 222 [88.8%]
Bullous keratopathy (pseudophakic, phakic IOL, buphthalmos, corneal perforation) 18 (14/1/2/1) [7.2%]
Failed DS(A)EK/PK, n [%] 9/1 [4.0%]
Average follow up period (±SD) [range] 5.7 (±1.1) years [4–7 years]

DMEK = Descemet membrane endothelial keratoplasty; DS(A)EK = Descemet stripping (automated) endothelial keratoplasty; IOL = intraocular lens; PK = penetrating keratoplasty; SD = standard deviation.


Graft Preparation


Harvesting of the DM graft was performed as previously described. In short, corneoscleral buttons from donor globes were obtained post mortem and stored in organ culture medium (31°C). In the eye bank, endothelial cell morphology and viability were evaluated and the corneoscleral buttons were mounted endothelial side up on a custom-made holder, so that a 9.5-mm-diameter DM sheet with its endothelium could be stripped off from the posterior stroma. Harvested “Descemet rolls” were then stored in organ culture medium until the day of transplantation.


Surgery


A circular 9.0-mm-diameter “descemetorrhexis” was performed under air, by scoring and stripping off the DM from the posterior stroma with a reversed Sinskey hook (DORC International, Zuidland, The Netherlands). The donor Descemet roll was stained (0.06% trypan blue solution; VisionBlue; DORC International), sucked into a custom-made injector (DMEK-inserter; DORC International) and injected through a 3.0-mm limbal tunnel incision into the recipient anterior chamber. The graft was oriented with the endothelial side facing the recipient iris and donor DM facing recipient stroma. After complete graft unfolding over the iris, an air bubble was injected underneath the graft to attach and fixate it onto the recipient posterior stroma. The anterior chamber was then completely filled with air for 60 minutes, followed by an air-liquid exchange, leaving a 30%–50% air bubble.


Postoperative medication included topical antibiotics for 2 weeks and a steroid regimen of dexamethasone 0.1% drops 4 times daily for 4 weeks, followed by fluorometholone drops 4 times daily, tapered to once daily until 1 year postoperatively and thereafter once daily or once every other day.


Data Collection and Analysis


All of the 250 eyes included in our study potentially had a follow-up of at least 4 years; 171 eyes, of 5 years; 87 eyes, of 6 years; and 32 eyes, a follow-up of 7 years after DMEK ( Table 2 ). Recipient eyes were examined before surgery and postoperatively at 6 months, at 1 year, and yearly thereafter. Pre- and postoperative best-corrected visual acuity (BCVA), ECD, and central corneal thickness (CCT) were measured using the Snellen visual acuity chart, noncontact autofocus specular microscopy (Topcon SP3000p; Topcon Medical Europe BV, Capelle a/d IJssel, The Netherlands), and Scheimpflug imaging (Pentacam HR; Oculus GmbH, Wetzlar, Germany), respectively. Postoperative complications were recorded in a database. Anterior segment optical coherence tomography (AS-OCT; Heidelberg Slit-Lamp OCT; Heidelberg Engineering GmbH, Heidelberg, Germany) was performed to evaluate graft adhesion status. Partial graft detachment greater than one third of the graft surface area was considered a “major” detachment. Partial detachment of less than or equal to one third of the graft surface area was considered a “minor” detachment.



Table 2

Available Eyes per Different Follow-up Intervals and Exclusion Criteria for Visual Acuity and Endothelial Cell Density Analysis


















































































































































Criteria Follow-up Interval
6 Months 1 Year 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years
Total number of eyes potentially available at FU 250 250 250 250 250 171 87 32
BCVA
Number (%) of eyes evaluated 208 (83.2%) 192 (76.8%) 171 (68.4%) 154 (61.6%) 146 (58.4%) 84 (49.1%) 49 (56.3%) 17 (53.1%)
Number (%) of eyes unavailable
Missing data or lost to follow-up 5 (2.0%) 15 (6.0%) 34 (13.6%) 52 (20.8%) 56 (22.4%) 51 (29.8%) 14 (16.1%) 4 (12.5%)
Secondary DSEK/repeat DMEK 17/1 (6.8%/0.4%) 23/5 (9.2%/2.0%) 23/9 (9.2%/3.6%) 23/12 (9.2%/4.8%) 23/13 (9.2%/5.2%) 20/9 (11.7%/5.3%) 16/6 (18.4%/6.9%) 10/1 (31.3%/3.1%)
Number (%) of eyes excluded
Low visual potential 19 (7.6%) 15 (6.0%) 13 (5.2%) 9 (3.6%) 12 (4.8%) 7 (4.1%) 2 (2.3%) 0 (0.0%)
Endothelial cell density
Number (%) of eyes evaluated 206 (82.4%) 193 (77.2%) 177 (70.8%) 160 (64%) 154 (61.6%) 89 (52%) 49 (56.3%) 17 (53.1%)
Number (%) of eyes unavailable/excluded 44 (17.6%) 57 (22.8%) 73 (29.2%) 90 (36.0%) 96 (38.4%) 82 (48.0%) 38 (43.7%) 15 (46.9%)
Missing data, unreliable data, or lost to follow-up 26 (10.4%) 29 (11.6%) 41 (16.4%) 55 (22.0%) 60 (24.0%) 53 (31.0%) 16 (18.4%) 4 (12.5%)
Secondary DSEK/repeat DMEK 17/1 (6.8%/0.4%) 23/5 (9.2%/2.0%) 23/9 (9.2%/3.6%) 23/12 (9.2%/4.8%) 23/13 (9.2%/5.2%) 20/9 (11.7%/5.3%) 16/6 (18.4%/6.9%) 10/1 (31.3%/3.1%)

BCVA = best-corrected visual acuity; DMEK = Descemet membrane endothelial keratoplasty; DSEK = Descemet membrane endothelial keratoplasty; ECD = endothelial cell density; FU = follow-up.


Endothelial graft failure was diagnosed with slit-lamp biomicroscopy (Topcon Medical Europe BV, Capelle a/d IJssel, The Netherlands), revealing corneal edema that necessitated repeat keratoplasty. Primary graft failure (PGF) was defined as the absence of corneal clearance after surgery despite full graft attachment and secondary graft failure (SGF) as a corneal decompensation due to donor endothelial failure after a postoperative interval with a clear cornea in an attached graft or in the presence of a minor graft detachment.


For BCVA analysis only cases with low visual potential owing to concomitant ocular pathology (retina or optic nerve disorders) were excluded, but not eyes with a graft detachment ( Table 2 ). For statistical analysis, BCVA values were converted to logarithm of the minimum angle of resolution (logMAR) units. Linear mixed models were used to evaluate how BCVA, ECD, and CCT values change over time after DMEK, while correcting for the covariates patient age, patient sex, lens status, and surgery indication. Sensitivity analyses were carried out to check whether the results were influenced by eyes with a major detachment, by the first 25 eyes operated (the learning curve), and by the inclusion of the second operated eye for some patients (n = 41). Survival analysis comprised 246 eyes (4 eyes had no follow-up information). A life table and a Kaplan-Meier curve display the graft survival probabilities. All multiple tests were controlled for false discovery rate and, as a result, all reported P values are corrected P values, which can be interpreted by comparing them directly with the significance level of .05. All analyses were performed with R.




Results


Visual Rehabilitation


At 4 years after DMEK, 96% of eyes reached a BCVA of ≥20/40 (≥0.5), 83% reached ≥20/25 (≥0.8), 54% ≥20/20 (≥1.0), and 22% ≥20/17 (≥1.2) ( Figure 1 , Top). From 5 to 7 years, these values were roughly similar ( Figure 1 , Top). The results of the linear mixed model showed that compared with preoperative values, BCVA (logMAR) improved significantly within the first 6 months after surgery (mean = −0.40, standard error [SE] = 0.02, P < .0001). From 6 months up to 7 years postoperatively BCVA remained stable (mean = −0.04, SE = 0.05, P = .7114). Sensitivity analysis showed that excluding eyes with a major graft detachment (n = 20) does not change the stabilization time point (6 months follow-up), but without these eyes the average improvement until 6 months follow-up would be even higher (mean = −0.45, SE = 0.02, P < .0001). Two covariates were significantly associated with BCVA outcomes: patient age ( P = .0016) and surgery indication. Fuchs endothelial dystrophy eyes have significantly better BCVA outcome compared with BK eyes, on average 0.13 points on the logMAR scale (SE = 0.04, P = .0016).




Figure 1


Clinical outcome up to 7 years after Descemet membrane endothelial keratoplasty (DMEK). (Top) Bar graph displaying the best-corrected visual acuity (BCVA) after DMEK at different follow-up intervals up to 7 years. (Middle) Graph displaying the mean endothelial cell density (ECD) after DMEK up to 7 years. ECD decrease compared with preoperative ECD are shown in bold and additional ECD decrease compared with the previous follow-up are shown in italics. (Bottom) Graph displaying the mean central corneal thickness (CCT) after DMEK up to 7 years. CCT decrease compared with preoperative CCT are shown in bold and additional CCT decrease compared with the previous follow-up are shown in italics.


Endothelial Cell Density


Donor ECD decreased from 2553 (±194) cells/mm 2 before surgery (n = 249) to 1687 (±521) cells/mm 2 at 6 months (n = 206), 1593 (±520) cells/mm 2 at 1 year (n = 193), and 1210 (±492) cells/mm 2 at 4 years (n = 154). At 6 years, ECD averaged 1037 (±429) cells/mm 2 (n = 49) and at 7 years, 903 (±429) cells/mm 2 (n = 17) ( Figure 1 , Middle). Hence, compared with preoperative values, ECD decreased by 33.9% within the first 6 months, by 37.6% at 1 year, and by 52.6% at 4 years. Compared with the previous follow-up, ECD decreased significantly at 6 months ( P < .0001). From 1 year on, a relatively “stable” average yearly ECD decrease of 9% was observed ( Figure 1 , Middle). None of the covariates was significantly associated with ECD decrease.


Central Corneal Thickness


CCT decreased by 21.4%, from 670 (±93) μm before surgery (n = 190) to 527 (±51) μm at 6 months (n = 189), 529 (±38) μm at 1 year (n = 188), 536 (±36) μm at 4 years (n = 142), and 550 (±51) μm at 7 years (n = 16). Compared with preoperative values, CCT decreased significantly at 6 months ( P < .0001). After the first 6 months, no change was found up to 7 years ( P = .8447) ( Figure 1 , Bottom). Covariates patient age ( P = .0005) and lens status ( P = .0047) were related to changes in CCT over time.


Complications


Of all postoperative complications (predominantly partial graft detachment), 88% (73/83) occurred within the first 6 months after surgery ( Table 3 , Figure 2 ). After 6 months, the remaining 12% (10/83) of complications were limited to secondary graft failure and allograft rejection episodes. Secondary graft failure occurred in 2% (5/250) of eyes and was attributed to endothelial failure in the presence of a minor graft detachment (1 eye), after a successful rebubbling procedure (1 eye), and after rejection (3 eyes of 2 patients). All secondary graft failures occurred after the 1-year follow-up, at various time points throughout the 7-year follow-up period ( Figure 2 , Table 3 ).



Table 3

Complications and Repeat Interventions in 250 Eyes up to 7 Years After Descemet Membrane Endothelial Keratoplasty




































































































Complications Occurrence Time Interval of Occurrence Resulting in Repeat Transplantation
Short-term, N Longer-term, N
% n ≤6 Months 6 Months–1 Year 1–2 Years 2–7 Years
Primary graft failure 1.6% 4 4 4
Secondary graft failure 2.0% 5 0 2 3 5
Minor detachment ≤1/3 11.6% 29 29 [1] a
Major detachment >1/3 15.6% 39 39 29 + [1] a
Allograft rejection episode 2.4% 6 1 1 1 3 [3] a
Reinterventions
Rebubbling (successful) 4.4% 11 11 (5) [6] b + [1] c
Secondary DSEK 9.6% 24 17 7
Repeat DMEK 5.6% 14 1 5 3 5

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jan 5, 2017 | Posted by in OPHTHALMOLOGY | Comments Off on Midterm Results of Descemet Membrane Endothelial Keratoplasty: 4 to 7 Years Clinical Outcome

Full access? Get Clinical Tree

Get Clinical Tree app for offline access